Shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $25.33 and traded as high as $25.37. Amplify Weight Loss Drug & Treatment ETF shares last traded at $25.36, with a volume of 850 shares traded.
Amplify Weight Loss Drug & Treatment ETF Stock Performance
The stock has a 50-day simple moving average of $25.57 and a 200 day simple moving average of $25.33. The stock has a market capitalization of $5.97 million, a P/E ratio of 24.31 and a beta of 0.42.
Amplify Weight Loss Drug & Treatment ETF Company Profile
The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Featured Articles
- Five stocks we like better than Amplify Weight Loss Drug & Treatment ETF
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Amplify Weight Loss Drug & Treatment ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Weight Loss Drug & Treatment ETF and related companies with MarketBeat.com's FREE daily email newsletter.
